[Therapy of mantle cell lymphoma].
Mantle cell lymphoma is characterized by an aggressive clinical course and poor prognosis, with only few long-term survivors. Conventional chemotherapy has failed to substantially alter the natural course of the disease and remains a palliative approach. However, several randomized trials have recently clearly demonstrated the superiority of a combined immunochemotherapy containing the anti-CD20 antibody rituximab. In addition, a randomized trial has shown a significantly improved progression-free survival after myeloablative radiochemotherapy with autologous stem cell transplantation similar to other dose-intensified approaches (hyper-CVAD). Unfortunately, the vast majority of patients will eventually relapse. However, numerous molecular targeting strategies (e.g. proteasome inhibitors, immunomodulatory drugs or radiolabeled antibodies) have achieved promising results in early phase II studies.
Dreyling
M
M
Med. Klinik und Poliklinik III, Klinikum der Universität München-Grosshadern, Marchioninistrasse 15, 81377, München, Deutschland. martin.dreyling@med.uni-muenchen.de
Unterhalt
M
M
Weigert
O
O
Hiddemann
W
W
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000628:therapy*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000639:trends; D016499:Radioimmunotherapy / Q000379:methods* / Q000639:trends*; D033581:Stem Cell Transplantation / Q000379:methods*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents